Skip to main content
. Author manuscript; available in PMC: 2022 Aug 26.
Published in final edited form as: JBJS Rev. 2021 Aug 26;9(8):10.2106/JBJS.RVW.20.00220. doi: 10.2106/JBJS.RVW.20.00220

TABLE II.

Clinical Trials in Gene Therapy for Arthritis

Indication Transgene Vector
(Delivery
Method)		 Phase National
Clinical Trial
(NCT)
Identifier		 Status
RA24 IL-1Ra Retrovirus Ex vivo I Predates the establishment of the NCT Completed
RA25 IL-1Ra Retrovirus Ex vivo I Predates the establishment of the NCT Completed
RA Etanercept AAV In vivo I 00617032 Completed
RA, psoriatic arthritis, ankylosing spondylitis Etanercept AAV In vivo I/II 00126724 Completed
OA TGF-β Retrovirus Ex vivo I, II, and III 02341391
02341378
02072070
01671072
00599248
03291470
03203330		 Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Not yet recruiting
RA, OA IFN-β AAV In vivo I 02727764 Not yet recruiting
RA IFN-β AAV In vivo I 03445715 Unknown
OA IL-1Ra AAV In vivo I 02790723 Completed
Recruiting
OA IL-1Ra Adenovirus In vivo I 04119687 Recruiting
OA IL-10 Plasmid In vivo I and II 03477487
04124042		 Completed
Active, not recruiting